IKZF1 and plasma cell myeloma: Lenalidomide recruits the neo-substrate IKZF1/3 onto CRBN and promotes ubiquitination and subsequent degradation by the CRL4CRBN E3 ligase, thereby exhibiting an anti-myeloma effect (7–9).